Article
Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations.
Molecular cancer therapeutics - 1 Jan 2018
Yamada Tadaaki, Amann Joseph M, Tanimoto Azusa, Taniguchi Hirokazu, Shukuya Takehito, Timmers Cynthia, Yano Seiji, Shilo Konstantin, Carbone David P
Abstract excerpt
Non-small cell lung cancer (NSCLC) can be identified by precise molecular subsets based on genomic alterations that drive tumorigenesis and include mutations in EGFR, KRAS, and various ALK fusions. However, despite effective treatments for EGFR and ALK, promising therapeutics have not been developed for patients with KRAS mutations. It has been reported that one way the RAS-ERK pathway contributes to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.